Ex­clu­sive: CSO George Yan­copou­los talks Re­gen­eron’s next chap­ter of ge­net­ics, weight loss drugs, and Alzheimer's

TAR­RY­TOWN, NY — Thir­ty-five years since they found­ed Re­gen­eron, the two out­spo­ken New York­ers atop the com­pa­ny are look­ing be­yond its vaunt­ed an­ti­body ex­per­tise as they plan for the next era.

While an­ti­body drugs such as Dupix­ent and Eylea have got­ten the most at­ten­tion, CEO Len Schleifer and CSO George Yan­copou­los have placed in­creas­ing­ly larg­er bets on ge­net­ics over the last decade. The Tar­ry­town, NY-based biotech has se­quenced over two mil­lion hu­man genomes while strik­ing a range of part­ner­ships to de­vel­op RNA- and DNA-mod­i­fy­ing ther­a­pies. Re­gen­eron re­cent­ly ac­quired Deci­bel Ther­a­peu­tics for its gene ther­a­py work, while it’s co-lead­ing clin­i­cal pro­grams with Al­ny­lam and In­tel­lia Ther­a­peu­tics, re­spec­tive­ly, us­ing RNA in­ter­fer­ence and CRISPR gene-edit­ing tech­nolo­gies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER